Literature DB >> 2269714

Clearance of ceftriaxone in critical care patients with acute renal failure.

G Heinemeyer1, J Link, W Weber, V Meschede, I Roots.   

Abstract

Serum concentrations of ceftriaxone (RocephinTM), a third generation cephalosporin, were monitored in 5 operative intensive care patients suffering from acute renal failure (ARF) and compared to those of 7 patients without renal disturbance. For a period of 7 days, a fixed dose of 2 g/day was given by a 15 min infusion. Pharmacokinetic parameters were calculated by fitting all serum and urine data measured over the period of treatment. Ceftriaxone free fraction was measured on days 2 and 7. There was no evidence for an intraindividual change in ceftriaxone-clearance during the observation period. Ceftriaxone renal clearance was closely dependent on creatinine clearance according to a linear regression expressed by Clren = 0.14 Clcrea + 2.2 (r = 0.951, p less than 0.0001). Total clearance was also associated with creatinine clearance: Cltot = 0.19 Clcrea + 8.2 (r = 0.964, p less than 0.0001). Related to the free fraction, renal clearance was in the range of the glomerular filtration rate. Non-renal clearance was strongly decreased when related to the free fraction indicating that biliary excretion is also impaired in patients with acute renal failure. Obviously no compensatory increase in hepatic ceftriaxone clearance takes place. It is concluded that elimination of ceftriaxone may be strongly impaired during acute renal failure in surgical intensive care patients and that dosage should be restricted according to degree of the impairment of creatinine clearance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2269714     DOI: 10.1007/bf01711224

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  17 in total

1.  Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? I. General considerations.

Authors:  P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

2.  Ceftriaxone: renal and biliary excretion and effect on the colon microflora.

Authors:  A Arvidsson; G Alván; B Angelin; O Borgå; C E Nord
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

3.  Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis.

Authors:  D Cohen; G B Appel; B Scully; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

4.  Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations.

Authors:  P J McNamara; M Gibaldi; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  [Acute kidney failure following major surgery].

Authors:  H P Schuster
Journal:  Dtsch Med Wochenschr       Date:  1980-11-21       Impact factor: 0.628

6.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

7.  Renal failure in the respiratory intensive care unit.

Authors:  S Kraman; F Khan; S Patel; N Seriff
Journal:  Crit Care Med       Date:  1979-06       Impact factor: 7.598

8.  Variability of ceftriaxone pharmacokinetics in hospitalized patients with severe infections.

Authors:  B Joos; R Luethy; E Muehlen; W Siegenthaler
Journal:  Am J Med       Date:  1984-10-19       Impact factor: 4.965

9.  Drug use in an intensive care unit and its relations to survival.

Authors:  R A Campos; F X Herraez; R J Marcos; J G Amer; R C Porcar; P I Lucia
Journal:  Intensive Care Med       Date:  1980-05       Impact factor: 17.440

Review 10.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

View more
  11 in total

Review 1.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

Review 2.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

4.  Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.

Authors:  Michael Schleibinger; Cathérine L Steinbach; Christoph Töpper; Alexander Kratzer; Uwe Liebchen; Frieder Kees; Bernd Salzberger; Martin G Kees
Journal:  Br J Clin Pharmacol       Date:  2015-06-11       Impact factor: 4.335

5.  Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal.

Authors:  Denis Garot; Renaud Respaud; Philippe Lanotte; Nicolas Simon; Emmanuelle Mercier; Stephan Ehrmann; Dominique Perrotin; Pierre-François Dequin; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

6.  An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review.

Authors:  C Jongmans; A E Muller; P Van Den Broek; B De Melo Cruz De Almeida; C Van Den Berg; J Van Oldenrijk; P K Bos; B C P Koch
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

7.  Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?

Authors:  Gloria Wong; Scott Briscoe; Syamhanin Adnan; Brett McWhinney; Jacobus Ungerer; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

8.  The kinetics of metamizol and its metabolites in critical-care patients with acute renal dysfunction.

Authors:  G Heinemeyer; H J Gramm; I Roots; R Dennhardt; W Simgen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Interaction between gentamicin and mycophenolate mofetil in experimentally induced pyelonephritis.

Authors:  H Malekinejad; A Nikibakhsh; S Gholizadeh-Soltani; A Farshid
Journal:  Indian J Nephrol       Date:  2012-01

Review 10.  Xenobiotic metabolism: the effect of acute kidney injury on non-renal drug clearance and hepatic drug metabolism.

Authors:  John Dixon; Katie Lane; Iain Macphee; Barbara Philips
Journal:  Int J Mol Sci       Date:  2014-02-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.